US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Azitra Inc

0.2465

-0.0155-5.92%

Post-market: 0.2412-0.0053-2.15%19:58 EDT

Volume:1.07M

Turnover:266.50K

Market Cap:4.25M

PE:-0.10

High:0.2554

Open:0.2500

Low:0.2410

Close:0.2620

Loading ...

Overview Company News Filings

Azitra Inc Plans Stock Increase at Annual Meeting

Azitra Inc. Shareholders to Vote on Proposal to Double Authorized Common Stock at Upcoming Annual Meeting

Azitra Inc. Announces Promising Safety Data from Phase 1b Trial of ATR12-351 for Netherton Syndrome

Azitra Inc - Atr12-351 Generally Safe and Well-Tolerated in Phase 1B Trial

THOMSON REUTERS

Azitra Inc - No Severe or Serious Adverse Events Reported in Atr12-351 Trial

THOMSON REUTERS

Azitra Reports Promising Safety Data From Phase 1B Trial in Netherton Syndrome

THOMSON REUTERS

Azitra Inc. Announces New Clinical Trials for ATR-12 and ATR-04 at 2025 BIO International Convention

Azitra Inc. to Present ATR-04 Clinical Trial Results at American Society of Clinical Oncology Annual Meeting

BRIEF-Azitra, Inc. Announces Q1 2025 Results And Provides Business Updates

Anitra Q1 EPS $(0.23) Up From $(4.32) YoY

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

THOMSON REUTERS

Press Release: Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership With Alumni Capital to Fund Clinical Pipeline

THOMSON REUTERS

Press Release: Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

AZTR: Netherton Topline Expected by Year-End

Zacks Small Cap Research

Maxim Group Reaffirms Their Buy Rating on Azitra Inc (AZTR)

Azitra FY24 EPS $(2.37) Vs $(54.98) YoY; Revenue $7.5K Vs $686K YoY

Press Release: Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Azitra Prices $930,000 Registered Direct Offering

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AZTR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AZTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZTR\",,,,,undefined,":{"symbol":"AZTR","market":"US","secType":"STK","nameCN":"Azitra Inc","latestPrice":0.2465,"timestamp":1750449600000,"preClose":0.262,"halted":0,"volume":1073035,"hourTrading":{"tag":"盘后","latestPrice":0.2412,"preClose":0.2465,"latestTime":"19:58 EDT","volume":86215,"amount":21105.6764,"timestamp":1750463883864},"delay":0,"floatShares":14858699,"shares":17226354,"eps":-2.369542,"marketStatus":"Market Closed","change":-0.0155,"latestTime":"06-20 16:00:00 EDT","open":0.25,"high":0.2554,"low":0.241,"amount":266503.908561,"amplitude":0.054962,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.369542,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"listingDate":1684382400000,"exchange":"AMEX","adjPreClose":0.262,"preHourTrading":{"tag":"盘前","latestPrice":0.25,"preClose":0.2509,"latestTime":"09:28 EDT","volume":40246,"amount":10157.023881,"timestamp":1750426104366},"postHourTrading":{"tag":"盘后","latestPrice":0.2412,"preClose":0.2465,"latestTime":"19:58 EDT","volume":86215,"amount":21105.6764,"timestamp":1750463883864},"volumeRatio":0.06694647236504536},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZTR\",,,,,undefined,":{"symbol":"AZTR","floatShares":14858699,"roa":"-116.11%","roe":"-208.50%","lyrEps":-2.369542,"volumeRatio":0.06694647236504536,"shares":17226354,"dividePrice":0,"high":0.2554,"amplitude":0.054962,"preClose":0.262,"low":0.241,"week52Low":0.2325,"pbRate":"0.96","psRate":"566.17","week52High":12,"institutionHeld":0,"latestPrice":0.2465,"eps":-2.369542,"divideRate":0,"volume":1073035,"delay":0,"ttmEps":-2.369542,"open":0.25,"prevYearClose":0.4255,"prevWeekClose":0.264,"prevMonthClose":0.274,"prevQuarterClose":0.303,"fiveDayClose":0.2855,"twentyDayClose":0.295,"sixtyDayClose":0.3332},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZTR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544185542","title":"Azitra Inc Plans Stock Increase at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544185542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544185542?lang=en_us&edition=fundamental","pubTime":"2025-06-19 05:53","pubTimestamp":1750283610,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Azitra Inc ( ($AZTR) ). Azitra, Inc. announced updates to its 2025 Annual Meeting of Stockholders, scheduled fo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/azitra-inc-plans-stock-increase-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/azitra-inc-plans-stock-increase-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2544154183","title":"Azitra Inc. Shareholders to Vote on Proposal to Double Authorized Common Stock at Upcoming Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544154183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544154183?lang=en_us&edition=fundamental","pubTime":"2025-06-19 05:22","pubTimestamp":1750281727,"startTime":"0","endTime":"0","summary":"Azitra Inc. has announced a virtual Annual Meeting of Stockholders scheduled for June 23, 2025, at 11:00 a.m. Eastern Time. Among the proposals, shareholders will vote on an amendment to the company's Second Amended and Restated Certificate of Incorporation to increase the authorized number of common stock shares from 100 million to 200 million. This proposal requires a majority of votes cast for approval, in line with recent changes to the Delaware General Corporation Law. The Board of Directors recommends voting in favor of this proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system op","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL3Kbhf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2544962861","title":"Azitra Inc. Announces Promising Safety Data from Phase 1b Trial of ATR12-351 for Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962861","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962861?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:02","pubTimestamp":1750161743,"startTime":"0","endTime":"0","summary":"Azitra Inc. has announced promising safety data from its Phase 1b trial of ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial, which is 50% enrolled, involves six patients who have received ATR12-351. The drug has been generally safe and well-tolerated, with only mild to moderate symptoms observed at the application site. The trial remains blinded, and no severe adverse events have been reported. Azitra is scheduled to present further details on this trial, along with its Phase 1/2 trial for ATR04-484, at the BIO International Convention in Boston on June 17, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL5w6SxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2544962858","title":"Azitra Inc - Atr12-351 Generally Safe and Well-Tolerated in Phase 1B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962858?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:02","pubTimestamp":1750161722,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA9NYDTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2544962855","title":"Azitra Inc - No Severe or Serious Adverse Events Reported in Atr12-351 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962855?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:02","pubTimestamp":1750161722,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA9NYDTX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2544962830","title":"Azitra Reports Promising Safety Data From Phase 1B Trial in Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962830?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:02","pubTimestamp":1750161722,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA9NYDTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2542314134","title":"Azitra Inc. Announces New Clinical Trials for ATR-12 and ATR-04 at 2025 BIO International Convention","url":"https://stock-news.laohu8.com/highlight/detail?id=2542314134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542314134?lang=en_us&edition=fundamental","pubTime":"2025-06-10 20:33","pubTimestamp":1749558805,"startTime":"0","endTime":"0","summary":"Azitra, Inc., a clinical stage biopharmaceutical company, has announced that it will present updates on its innovative therapies at the 2025 BIO International Convention in Boston, Massachusetts. The presentation, scheduled for June 17, will provide recent updates on Azitra's pipeline, including ATR-12, which is currently in a Phase 1b clinical trial for adult patients with Netherton syndrome, and ATR-04, under development for addressing moderate to severe EGFRi-associated dermal toxicity in adults. The results of these studies will be presented by Travis Whitfill, PhD MPH, Cofounder and Chief Operating Officer of Azitra, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL13bcz2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2538447680","title":"Azitra Inc. to Present ATR-04 Clinical Trial Results at American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538447680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538447680?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:33","pubTimestamp":1748435601,"startTime":"0","endTime":"0","summary":"Azitra, Inc., a clinical stage biopharmaceutical company, will present at the 2025 American Society of Clinical Oncology Annual Meeting, taking place from May 30 to June 3, 2025, in Chicago. They will showcase a poster on their Phase 1/2 clinical trial of ATR04-484, focusing on the treatment of EGFR inhibitor-induced dermal toxicity with a novel _Staphylococcus epidermidis_ compound.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL4mRd3w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2535354140","title":"BRIEF-Azitra, Inc. Announces Q1 2025 Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535354140","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535354140?lang=en_us&edition=fundamental","pubTime":"2025-05-14 06:15","pubTimestamp":1747174537,"startTime":"0","endTime":"0","summary":"BRIEF-Azitra, Inc. Announces Q1 2025 Results And Provides Business UpdatesMay 13 (Reuters) - Azitra Inc AZTR.A:AZITRA, INC. ANNOUNCES Q1 2025 RESULTS AND PROVIDES BUSINESS UPDATESSource text: ID:nPn5RMYJTaFurther company coverage: AZTR.A ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA7KJ2XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2535003882","title":"Anitra Q1 EPS $(0.23) Up From $(4.32) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535003882","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535003882?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:08","pubTimestamp":1747170526,"startTime":"0","endTime":"0","summary":"Anitra (AMEX:AZTR) reported quarterly losses of $(0.23) per share. This is a 94.68 percent increase over losses of $(4.32) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45393030/anitra-q1-eps-0-23-up-from-4-32-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR"],"gpt_icon":0},{"id":"2535080059","title":"Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535080059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535080059?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:06","pubTimestamp":1747170364,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA7KJ2XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2535038351","title":"Press Release: Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535038351","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535038351?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:06","pubTimestamp":1747170360,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update.-- Announced acceptance of poster detailing the Phase 1/2 clinical trial of. the ATR-04 program in EGFR inhibitor -associated rash at the. 2025 American Society of Clinical Oncology  Annual Meeting. -- Entered into Purchase Agreement for up to $20 Million in Partnership with. institutional investor Alumni Capital LP, to fund clinical pipeline. \"The start of 2025 has been a vital period for Azitra as we build towards key milestones expected by mid-year for our first-in-class, precision, live biotherapeutic candidates designed for major undertreated dermatological diseases,\" said Francisco Salva, CEO of Azitra. \"For ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we expect to ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2530138857","title":"Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530138857","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530138857?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:33","pubTimestamp":1745584380,"startTime":"0","endTime":"0","summary":"Azitra is developing ATR04-484 for the treatment ofEGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025. BRANFORD,Conn., April 25, 2025 /PRNewswire/ -- Azitra, Inc. , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that an abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor -associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology  Annual Meeting being held May 30-June 3, 2025 in Chicago.Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profoun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/azitra-inc-present-atr-04-123300411.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azitra-inc-present-atr-04-123300411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATR","BK4126","BK4139","AZTR"],"gpt_icon":0},{"id":"2530606209","title":"Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership With Alumni Capital to Fund Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2530606209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530606209?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:05","pubTimestamp":1745525115,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUAC40BTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2530960148","title":"Press Release: Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2530960148","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530960148?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:05","pubTimestamp":1745525100,"startTime":"0","endTime":"0","summary":"Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline. BRANFORD, Conn., April 24, 2025 /PRNewswire/ -- Azitra, Inc. , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a share purchase agreement  with Alumni Capital LP , an institutional investor. Azitra anticipates that this partnership will provide Azitra with a flexible source of funding, enabling the Company to progress its pipeline of live biotherapeutic precision products delivered topically to treat rare and severe dermatologic conditions.Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton sy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2516563271","title":"AZTR: Netherton Topline Expected by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2516563271","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516563271?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:39","pubTimestamp":1740994740,"startTime":"0","endTime":"0","summary":"Azitra, Inc.  reported 2024 results in a February press release highlighting several achievements and company goals. The Phase Ib clinical trial for ATR-12 in Netherton syndrome has started and is expected to produce initial safety data in the next few months. Activity is robust for the ATR-04 program in EGFRi skin rash with Fast Track status and FDA clinical study clearance granted for a Phase I/II study. The ATR-04 trial is slated to begin this spring. Other activity includes capital raises to support the clinical trial work and new patents granted and allowed. Azitra management has been busy participating in several investor and industry conferences including the Microcap Conference, Biotech Showcase, BIO-CEO and the European Academy of Dermatology meetings.Following the end of the reporting period, Azitra raised an additional $2.2 mil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aztr-netherton-topline-expected-end-093900351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2514661848","title":"Maxim Group Reaffirms Their Buy Rating on Azitra Inc (AZTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514661848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514661848?lang=en_us&edition=fundamental","pubTime":"2025-02-27 02:06","pubTimestamp":1740593160,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Azitra Inc (AZTR – Research Report). The company’s share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-azitra-inc-aztr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-azitra-inc-aztr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZTR"],"gpt_icon":0},{"id":"2513729282","title":"Azitra FY24 EPS $(2.37) Vs $(54.98) YoY; Revenue $7.5K Vs $686K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729282","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729282?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:37","pubTimestamp":1740404255,"startTime":"0","endTime":"0","summary":"Azitra FY24 EPS $(2.37) Vs $(54.98) YoY; Revenue $7.5K Vs $686K YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43911070/azitra-fy24-eps-2-37-vs-54-98-yoy-revenue-7-5k-vs-686k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Azitra FY24 EPS $(2.37) Vs $(54.98) YoY; Revenue $7.5K Vs $686K YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR"],"gpt_icon":0},{"id":"2513272912","title":"Press Release: Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513272912?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update.-- Initiated a Phase 1b clinical trial investigating ATR-12 in adult. Netherton syndrome patients; Initial safety data from first set of. -- Received clearance from the U.S. Food and Drug Administration  for a. -- FDA granted Fast Track designation to ATR-04, demonstrating that the FDA. Salva continued, \"In addition to ATR-12, Azitra has made significant progress with our next most advanced product, ATR-04. ATR-04 is a live biotherapeutic product candidate containing an isolated, naturally derived S. epidermidis strain being developed for the treatment of EGFR inhibitor  associated rash, which impacts approxim","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","LU1481600234.SGD","SID","LU1481599808.USD","AZTR","BK4588","IP","BK4585","BK4136","BK4139","LU1487256676.USD","LU2463526074.USD"],"gpt_icon":0},{"id":"2509956874","title":"Azitra Prices $930,000 Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509956874","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509956874?lang=en_us&edition=fundamental","pubTime":"2025-02-05 03:48","pubTimestamp":1738698512,"startTime":"0","endTime":"0","summary":"Azitra  said Tuesday it has priced a registered direct offering of about 3.34 million common shares at $0.2785 per share to raise nearly $930,000 in gross proceeds.Azitra said it plans to use the net proceeds from the offering for working capital and general corporate purposes.The offering is set to close on Wednesday, pending customary closing conditions.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AZTR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZTR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-07-01","symbol":"AZTR","defaultRemindTime":1719840600000,"type":"split","dateTimestamp":1719806400000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZTR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1709265600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AZTR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AZTR","date":"2025-06-20","current":-0.495806,"percent":0.60251,"low":-5.58964,"twenty":-1.390002,"median":-0.531215,"eighty":-0.413237,"high":-0.185344,"avg":-1.017599,"sd":1.096247,"marketCap":4513304},"quantilePoints":[{"date":"2023-06-16","current":-5.58964,"twenty":-5.58964,"median":-5.58964,"eighty":-5.58964,"marketCap":60432550},{"date":"2023-06-23","current":-5.399592,"twenty":-5.535979,"median":-5.477847,"eighty":-5.319101,"marketCap":58377843},{"date":"2023-06-30","current":-4.158692,"twenty":-5.495734,"median":-4.997138,"eighty":-4.683,"marketCap":44961817},{"date":"2023-07-07","current":-4.102796,"twenty":-5.446545,"median":-4.779142,"eighty":-4.362155,"marketCap":44357491},{"date":"2023-07-14","current":-4.516429,"twenty":-5.23861,"median":-4.527608,"eighty":-4.362155,"marketCap":48829500},{"date":"2023-07-21","current":-4.471712,"twenty":-4.912176,"median":-4.545495,"eighty":-4.476184,"marketCap":48346040},{"date":"2023-07-28","current":-4.046899,"twenty":-4.782496,"median":-4.527608,"eighty":-4.268249,"marketCap":43753166},{"date":"2023-08-04","current":-2.683027,"twenty":-4.767963,"median":-4.499884,"eighty":-4.151985,"marketCap":29007624},{"date":"2023-08-11","current":-3.040764,"twenty":-4.731474,"median":-4.477302,"eighty":-4.060314,"marketCap":32875307},{"date":"2023-08-18","current":-2.775015,"twenty":-4.690311,"median":-4.281664,"eighty":-3.058651,"marketCap":30002154},{"date":"2023-08-25","current":-1.902871,"twenty":-4.641637,"median":-4.231357,"eighty":-2.884254,"marketCap":25405050},{"date":"2023-09-01","current":-1.803197,"twenty":-4.5827,"median":-4.147513,"eighty":-2.714329,"marketCap":24074309},{"date":"2023-09-08","current":-1.902871,"twenty":-4.560878,"median":-4.102796,"eighty":-2.060538,"marketCap":25405050},{"date":"2023-09-15","current":-1.585817,"twenty":-4.544154,"median":-3.834493,"eighty":-1.953615,"marketCap":21172085},{"date":"2023-09-21","current":-1.61291,"twenty":-4.538788,"median":-3.091071,"eighty":-1.911933,"marketCap":21533804},{"date":"2023-09-29","current":-1.449807,"twenty":-4.516429,"median":-3.018406,"eighty":-1.812258,"marketCap":19356228},{"date":"2023-10-06","current":-1.359194,"twenty":-4.516429,"median":-2.884254,"eighty":-1.757891,"marketCap":18146464},{"date":"2023-10-13","current":-1.223274,"twenty":-4.499884,"median":-2.775015,"eighty":-1.61291,"marketCap":16331818},{"date":"2023-10-20","current":-1.631033,"twenty":-4.482891,"median":-2.442461,"eighty":-1.531358,"marketCap":21775757},{"date":"2023-10-27","current":-1.495113,"twenty":-4.482891,"median":-2.138465,"eighty":-1.509611,"marketCap":19961110},{"date":"2023-11-03","current":-1.40441,"twenty":-4.478419,"median":-1.984423,"eighty":-1.435308,"marketCap":18750136},{"date":"2023-11-10","current":-1.694462,"twenty":-4.458297,"median":-1.96177,"eighty":-1.420811,"marketCap":22622592},{"date":"2023-11-17","current":-1.465632,"twenty":-4.37557,"median":-1.920994,"eighty":-1.431684,"marketCap":18872323},{"date":"2023-11-24","current":-1.211965,"twenty":-4.277192,"median":-1.902871,"eighty":-1.413562,"marketCap":15605959},{"date":"2023-12-01","current":-0.977088,"twenty":-4.25707,"median":-1.832646,"eighty":-1.395439,"marketCap":12581548},{"date":"2023-12-08","current":-0.920718,"twenty":-4.241419,"median":-1.803197,"eighty":-1.359194,"marketCap":11855690},{"date":"2023-12-15","current":-1.343496,"twenty":-4.20341,"median":-1.74883,"eighty":-1.354152,"marketCap":17299629},{"date":"2023-12-22","current":-1.207362,"twenty":-4.156456,"median":-1.638553,"eighty":-1.313887,"marketCap":15546681},{"date":"2023-12-29","current":-0.995972,"twenty":-4.149749,"median":-1.634793,"eighty":-1.283368,"marketCap":12824711},{"date":"2024-01-05","current":-0.995878,"twenty":-4.143041,"median":-1.631033,"eighty":-1.233783,"marketCap":12823501},{"date":"2024-01-12","current":-0.972391,"twenty":-4.122919,"median":-1.585771,"eighty":-1.215761,"marketCap":12521060},{"date":"2024-01-19","current":-1.925991,"twenty":-4.098324,"median":-1.585771,"eighty":-1.213863,"marketCap":24800168},{"date":"2024-01-26","current":-1.249546,"twenty":-4.073729,"median":-1.531358,"eighty":-1.221818,"marketCap":16089865},{"date":"2024-02-02","current":-1.089829,"twenty":-3.961937,"median":-1.519884,"eighty":-1.211965,"marketCap":14033265},{"date":"2024-02-09","current":-0.967693,"twenty":-3.517002,"median":-1.493818,"eighty":-1.195054,"marketCap":12460572},{"date":"2024-02-16","current":-0.833723,"twenty":-3.094425,"median":-1.466781,"eighty":-1.167586,"marketCap":10735497},{"date":"2024-02-23","current":-0.571872,"twenty":-3.085481,"median":-1.465632,"eighty":-1.12741,"marketCap":7363748},{"date":"2024-03-01","current":-0.569638,"twenty":-3.040764,"median":-1.449807,"eighty":-1.080434,"marketCap":7334983},{"date":"2024-03-08","current":-0.5091,"twenty":-3.018406,"median":-1.436214,"eighty":-1.024064,"marketCap":6555462},{"date":"2024-03-15","current":-0.533896,"twenty":-2.973688,"median":-1.413562,"eighty":-0.986483,"marketCap":6874749},{"date":"2024-03-22","current":-0.577176,"twenty":-2.884254,"median":-1.406836,"eighty":-0.977088,"marketCap":6512729},{"date":"2024-03-28","current":-0.512081,"twenty":-2.884254,"median":-1.395439,"eighty":-0.95454,"marketCap":5778211},{"date":"2024-04-05","current":-0.602448,"twenty":-2.82165,"median":-1.381077,"eighty":-0.91696,"marketCap":6797895},{"date":"2024-04-12","current":-0.465876,"twenty":-2.781212,"median":-1.359194,"eighty":-0.858373,"marketCap":5256847},{"date":"2024-04-19","current":-0.484509,"twenty":-2.764029,"median":-1.359194,"eighty":-0.602141,"marketCap":5467092},{"date":"2024-04-26","current":-0.56186,"twenty":-2.698678,"median":-1.348194,"eighty":-0.592185,"marketCap":6339901},{"date":"2024-05-03","current":-0.561349,"twenty":-2.298121,"median":-1.33201,"eighty":-0.590246,"marketCap":6334140},{"date":"2024-05-10","current":-0.634358,"twenty":-2.100408,"median":-1.309357,"eighty":-0.590246,"marketCap":7157953},{"date":"2024-05-17","current":-0.485733,"twenty":-2.060538,"median":-1.287126,"eighty":-0.577789,"marketCap":5711960},{"date":"2024-05-24","current":-0.495041,"twenty":-1.998921,"median":-1.258941,"eighty":-0.571425,"marketCap":5821418},{"date":"2024-05-31","current":-0.477649,"twenty":-1.978986,"median":-1.23641,"eighty":-0.56671,"marketCap":5616905},{"date":"2024-06-07","current":-0.40441,"twenty":-1.975362,"median":-1.223274,"eighty":-0.560644,"marketCap":4755646},{"date":"2024-06-14","current":-0.355665,"twenty":-1.964488,"median":-1.211965,"eighty":-0.547207,"marketCap":4182434},{"date":"2024-06-21","current":-0.348806,"twenty":-1.948178,"median":-1.211965,"eighty":-0.531751,"marketCap":4101781},{"date":"2024-06-28","current":-0.323332,"twenty":-1.948178,"median":-1.207362,"eighty":-0.527437,"marketCap":3802212},{"date":"2024-07-05","current":-0.191876,"twenty":-1.946474,"median":-1.193175,"eighty":-0.519324,"marketCap":2256361},{"date":"2024-07-12","current":-0.262095,"twenty":-1.936747,"median":-1.171479,"eighty":-0.513791,"marketCap":3082094},{"date":"2024-07-15","current":-0.249847,"twenty":-1.933161,"median":-1.16499,"eighty":-0.513107,"marketCap":2938071},{"date":"2024-08-02","current":-0.505188,"twenty":-1.929576,"median":-1.160292,"eighty":-0.511877,"marketCap":5940751},{"date":"2024-08-09","current":-0.326677,"twenty":-1.921993,"median":-1.12741,"eighty":-0.508698,"marketCap":3841548},{"date":"2024-08-16","current":-0.508927,"twenty":-1.913745,"median":-1.094479,"eighty":-0.508559,"marketCap":5069899},{"date":"2024-08-23","current":-0.572533,"twenty":-1.904683,"median":-1.080434,"eighty":-0.504719,"marketCap":5703541},{"date":"2024-08-30","current":-0.491781,"twenty":-1.902871,"median":-1.028761,"eighty":-0.504719,"marketCap":4899098},{"date":"2024-09-06","current":-0.446316,"twenty":-1.872969,"median":-0.995925,"eighty":-0.498634,"marketCap":4446170},{"date":"2024-09-13","current":-0.447771,"twenty":-1.828568,"median":-0.986483,"eighty":-0.492929,"marketCap":4460665},{"date":"2024-09-20","current":-0.458486,"twenty":-1.806821,"median":-0.986483,"eighty":-0.488525,"marketCap":4567408},{"date":"2024-09-27","current":-0.425726,"twenty":-1.803197,"median":-0.972391,"eighty":-0.483591,"marketCap":4241056},{"date":"2024-10-04","current":-0.382709,"twenty":-1.797955,"median":-0.948903,"eighty":-0.474913,"marketCap":3812528},{"date":"2024-10-11","current":-0.380413,"twenty":-1.788828,"median":-0.939508,"eighty":-0.460002,"marketCap":3789652},{"date":"2024-10-18","current":-0.447829,"twenty":-1.768764,"median":-0.901928,"eighty":-0.454812,"marketCap":4461242},{"date":"2024-10-25","current":-0.421035,"twenty":-1.747017,"median":-0.864535,"eighty":-0.451467,"marketCap":4194330},{"date":"2024-10-31","current":-0.390568,"twenty":-1.721646,"median":-0.679541,"eighty":-0.447115,"marketCap":3890813},{"date":"2024-11-08","current":-0.387353,"twenty":-1.672098,"median":-0.649036,"eighty":-0.440762,"marketCap":3858784},{"date":"2024-11-15","current":-0.381043,"twenty":-1.638553,"median":-0.603725,"eighty":-0.431797,"marketCap":3440113},{"date":"2024-11-22","current":-0.397008,"twenty":-1.635545,"median":-0.600404,"eighty":-0.42943,"marketCap":3584246},{"date":"2024-11-29","current":-0.443466,"twenty":-1.631033,"median":-0.593224,"eighty":-0.428634,"marketCap":4003679},{"date":"2024-12-06","current":-0.406469,"twenty":-1.627408,"median":-0.591753,"eighty":-0.425604,"marketCap":3669658},{"date":"2024-12-13","current":-0.397684,"twenty":-1.607491,"median":-0.589174,"eighty":-0.420859,"marketCap":3590347},{"date":"2024-12-20","current":-0.333825,"twenty":-1.585799,"median":-0.580807,"eighty":-0.418884,"marketCap":3013817},{"date":"2024-12-27","current":-0.344383,"twenty":-1.585726,"median":-0.577176,"eighty":-0.415622,"marketCap":3109143},{"date":"2025-01-03","current":-0.375722,"twenty":-1.584421,"median":-0.573602,"eighty":-0.411894,"marketCap":3392069},{"date":"2025-01-10","current":-0.331628,"twenty":-1.552453,"median":-0.572533,"eighty":-0.405083,"marketCap":2993989},{"date":"2025-01-17","current":-0.227224,"twenty":-1.531358,"median":-0.570755,"eighty":-0.401631,"marketCap":2051409},{"date":"2025-01-24","current":-0.212948,"twenty":-1.527616,"median":-0.567057,"eighty":-0.398783,"marketCap":1922528},{"date":"2025-01-31","current":-0.213033,"twenty":-1.520308,"median":-0.56186,"eighty":-0.398223,"marketCap":1923291},{"date":"2025-02-07","current":-0.326307,"twenty":-1.508705,"median":-0.560468,"eighty":-0.394676,"marketCap":2945945},{"date":"2025-02-14","current":-0.697553,"twenty":-1.494595,"median":-0.56186,"eighty":-0.397008,"marketCap":6297608},{"date":"2025-02-21","current":-0.716832,"twenty":-1.48864,"median":-0.56671,"eighty":-0.397143,"marketCap":6471662},{"date":"2025-02-28","current":-0.586313,"twenty":-1.46747,"median":-0.568521,"eighty":-0.397761,"marketCap":5257753},{"date":"2025-03-07","current":-0.551234,"twenty":-1.465633,"median":-0.567404,"eighty":-0.398147,"marketCap":4943186},{"date":"2025-03-14","current":-0.579297,"twenty":-1.465632,"median":-0.571576,"eighty":-0.398458,"marketCap":5194839},{"date":"2025-03-21","current":-0.547893,"twenty":-1.462467,"median":-0.571872,"eighty":-0.398521,"marketCap":4913228},{"date":"2025-03-28","current":-0.546223,"twenty":-1.449807,"median":-0.568521,"eighty":-0.398697,"marketCap":4898248},{"date":"2025-04-04","current":-0.490264,"twenty":-1.449214,"median":-0.56671,"eighty":-0.39874,"marketCap":4396440},{"date":"2025-04-11","current":-0.467714,"twenty":-1.445623,"median":-0.562229,"eighty":-0.39905,"marketCap":4194219},{"date":"2025-04-17","current":-0.531189,"twenty":-1.440745,"median":-0.561476,"eighty":-0.399601,"marketCap":4763434},{"date":"2025-04-25","current":-0.511144,"twenty":-1.431684,"median":-0.559586,"eighty":-0.401232,"marketCap":4583682},{"date":"2025-05-02","current":-0.547893,"twenty":-1.431684,"median":-0.554496,"eighty":-0.401897,"marketCap":4913228},{"date":"2025-05-09","current":-0.497614,"twenty":-1.413562,"median":-0.551234,"eighty":-0.40441,"marketCap":4462349},{"date":"2025-05-16","current":-0.461576,"twenty":-1.413562,"median":-0.548728,"eighty":-0.404526,"marketCap":4201708},{"date":"2025-05-23","current":-0.46931,"twenty":-1.409262,"median":-0.546223,"eighty":-0.405455,"marketCap":4272111},{"date":"2025-05-30","current":-0.445943,"twenty":-1.40538,"median":-0.543447,"eighty":-0.406266,"marketCap":4059404},{"date":"2025-06-06","current":-0.496845,"twenty":-1.397233,"median":-0.53771,"eighty":-0.408893,"marketCap":4522759},{"date":"2025-06-13","current":-0.540277,"twenty":-1.395439,"median":-0.535799,"eighty":-0.411894,"marketCap":4918124},{"date":"2025-06-20","current":-0.495806,"twenty":-1.390002,"median":-0.531215,"eighty":-0.413237,"marketCap":4513304}],"updateTime":1750554248908}}}